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Neurons expressing the m,, m2, and m4 muscarinic receptor genes in the adult rat striatum were identified and characterized by using several in situ hybridization and immunohistochemical procedures. Combined in situ hybridization for the simultaneous detection of two mRNAs in the same section or in adjacent sections as well as in situ hybridization and immunohistochemistry on adjacent sections permitted us to identify the neurons containing m,, m2, or m4 receptor mRNA. Our observations demonstrate that m,, m2, and m, receptor genes are expressed in one or several phenotypically distinct neuronal populations. The m, receptor gene was the most widely expressed (85% of the striatal neurons). Most cholinergic neurons (80% or more) contain m,, m2, and m4 receptor mRNAs. Almost all the substance P neurons contain m, and m, receptor mRNA. All enkephalinergic neurons contained m, receptor mRNA, but only 39% contained m4 receptor mRNA. Most somatostatin and neurotensin neurons expressed the m, receptor gene, but only a few (15% and 9%, respectively) contained m, receptor mRNA.
The present study offers anatomical evidence that ACh may act directly in complex ways on the main neuronal populations of the striatum through muscarinic receptors. The m,, m2, and m4 receptors may act as autoreceptors to control ACh release and possibly other parameters of ACh neurons. On the other hand, the m, and m, receptors may act as heteroreceptors in cholinoceptive efferent neurons (enkephalin and substance P neurons) and other neurons (somatostatin/neuropeptide Y and neurotensin neurons). The presence of m4 receptor mRNA in only parts of the enkephalin, somatostatin, and neurotensin neuronal populations indicates that muscarinic receptor gene expression contributes to the functional and anatomical heterogeneity of the striatum that may relate to higher order of organization, including patch-matrix compartmentalization.
The wide expression of m, and m4 receptor genes in the striatum sug-gests that ACh may directly influence neurotransmitter release and synthesis in striatal efferent and intrinsic neurons. Our results imply that the specific pattern of expression of the muscarinic receptor genes mediates direct effects of ACh on activities and functions of chemically and topologically defined striatal neuronal populations.
Since the expression of muscarinic receptors occurred in the three main neuronal populations of the striatum, namely ACh, enkephalins, and substance P neurons that also express dopamine receptors, it is highly probable that ACh and dopamine may act together at the single-cell level to influence striatal functions.
Various anatomical, electrophysiological, and pathological observations provide evidence that ACh plays a major role in the control of striatal function and in particular in the regulation of motor control (Homykiewicz, 198 1; Jabbari et al., 1989) . Striatal ACh is released from a population of large cholinergic intemeurons that establish complex synaptic contacts with dopamine terminals, originating from the substantia nigra, and with several striatal neuronal populations Langer, 1982, 1983; Wainer et al., 1984; Phelps et al., 1985; Izzo and Bolam, 1988; Vuillet et al., 1992) . The anatomical and physiological bases of interactions between ACh neurons and dopamine endings in the striatum have been well documented (Lehmann and Langer, 1983) . ACh directly controls dopamine release in complex ways (stimulation or inhibition) depending on the striosome/matrix compartmentalization (Kernel et al., 1989; Gauchy et al., 199 1) . ACh and dopamine most probably interact to promote normal movements as seen from the effects ofACh antagonists or dopamine agonists that each reduce motor disorders observed in Parkinson's disease (Homykiewicz, 198 1) .
Several lines of evidence also suggest that ACh may influence directly the activity ofother striatal neurons: ACh exerts a direct excitatory influence on efferent neurons (Gauchy et al., 1992) and facilitates GABA release (Besson et al., 1987) while muscarinic receptor activation inhibits GABA release (Marchi et al., 1990; Sugita et al., 1991) . Cholinergic neurons establish synaptic contact with medium-sized spiny or aspiny neurons (Wainer et al., 1984; Phelps et al., 1985; Vuillet et al., 1991) while muscarinic and nicotinic receptors have been described in the striatum (Clarke et al., 1984; Spencer et al., 1986; Levey et al., 199 1; Vilaro et al., I99 1) . Moreover, in situ hybridization (ISH) experiments have demonstrated that several ACh receptor genes, including the m,, m,, and m4 muscarinic receptor (m,R, m,R, and m,R) genes are expressed by striatal neurons with specific patterns of localization (Buckley et al., 1988; Wada et al., 1989; Weiner et al., 1990; Vilaro et al., 1991) . In contrast, the other muscarinic receptor genes so far identified (m,R and m,R) are not expressed by striatal neurons (Buckley et al., 1988; Weiner et al., 1990) . Taken together, these results demonstrate that certain striatal neurons are direct targets for ACh through the action of m,R, m,R, and m,R. Neuronal interactions in the striatum are complex and involve several chemically and topologically defined neuronal populations (Graybiel, 1990) . This includes the ACh neurons themselves and several peptidergic neurons, most of which are also GABAergic. Of the latter, neurons producing either substance P/dynorphin (SP/DYN) or enkephalins are efferent neurons that project to the substantia nigra and the globus pallidus, respectively. They constitute over 90% of the medium-sized spiny neurons in the striatum. Other neuronal populations include neurotensin (NT) and somatostatin/ neuropeptide Y (SRIF/NPY) neurons, which are less abundant; the latter project locally in the striatum.
In view of establishing a neuroanatomical basis for ACh actions on striatal neurons, we have developed strategies to establish which chemically defined neurons express which muscarinic receptor subtype genes. For this we used several methods involving ISH and immunohistochemistry that we have previously shown to be useful for the phenotypical characterization of neurons expressing dopamine receptor genes (Le Moine et al., 1990a Moine et al., ,b, 1991 Le Moine and Bloch, 1991; Normand and Bloch, 199 1) . Our present results demonstrate that each muscarinic receptor gene known to be expressed in the striatum (m,R, m,R, and m,R) (Buckley et al., 1988; Weiner et al., 1990; Vilaro et al., 199 1) displays a specific spatial expression in one or several chemically defined neuronal populations.
Materials and Methods

.4nimals and tissue preparation
The experiments were performed on IO adult male rats (Wistar, Iffa Credo, L'Arbresle, France). The animals were anesthetized with pentobarbital and perfused through the heart with 1% paraformaldehyde in sodium phosphate buffer. The brains were dissected, placed in the fixative for 1 hr, left in sucrose/phosphate buffer overnight, and then frozen over liquid nitrogen (Bloch et al., 1986) . Frontal serial sections (3pm, 4Fm, or IOFm) were then cut on a cryostat, collected on gelatincoated slides, and stored at -80°C until use. Sections 3 and 4 pm thick were indexed by pairs of adjacent sections.
Probe preparation and labeling
Synthetic oligonucleotide probes were used to detect m,R, m,R, m,R, SP, SRIF, and NT mRNA. The sequences were chosen on the basis of the cloned sequences (m,R and m,R: GenBank accession numbers Ml 6406 and M 16409; m,R: Gocayne et al., 1987; SP: Nawa et al., 1983; SRIF: Funckes et al., 1983; NT: Kislauskis et al., 1988) . The sequences of the oligonucleotides were as follows: m,R, 5'-TGA CCT CTCTGAGCTGCTGCTGCTGCCACCACCTTTGCCTGG TGT CTC-3'; m,R, 5'-TCA CAT ACT ACA GGT CCC AAA GGC CAG TAG CCA-ATC ACA GTG TAG AGG-3'; m,R, S-CGT TCC TTG GTG TTC TGG GTG GCA CTG CCT GAG CTG GAC TCA TTG GAA-3'; SP, 5'-CCC TTT CCC CAT CAA TCC AAA GAA CTG CTG AGG CTT GGG TCT CCG-3'; SRIF, 5'-CCA GAA GAA GTT CTT GCA GCC AGC TTT GCG TTC CCG GGG TGC CAT-3'; NT, 5'-GGC CCG GCT GCG GCA GAT CTT CTG GAG TTG GAA TAC GGT CAG CAG CCC-3'. Preproenkephalin A (PPA) mRNA (used as a marker of the enkephalin neurons) was detected either with an oliaonucleotide probe (5'-GTC CAT CCA CCA CTC TGG ACG ACC TAC TCT TCT CA? GAA GCC CCC-3'; Comb et al., 1982) or with a 0.4 kb fragment of the cDNA cloned by Yoshikawa (Yoshikawa et al.. 1984) . Oliaonucleotide m,R. m,R. m,R. SP. NT. and PPA urobes were labeled with aJ5S-thio-dA?P iNkw England Niclear; specific activity, 2 x 10' cpm/Fg) and SRIF probe with biotin 16 dUTP (Enzo Biochem) by tailing procedure using terminal deoxynucleotidyl transferase (Amersham). The PPA cDNA probe was labeled by nick-translation with biotin 16 dUTP (Guitteny et al., 1988; Le Moine et al., 1991) .
In situ hybridization and phenotypical identt$cation qf cells expressing muscarinic receptor genes The phenotypes of the cells expressing the muscarinic receptor genes were identified using three different procedures: (I) localization of two mRNAs on adjacent sections (3 Frn thick), (2) simultaneous visualization of two mRNAs by combined hybridization using radioactive and biotinylated probes on the same section, and (3) localization of muscarinic receptor mRNA by ISH and choline acetyltransferase by immunohistochemistry on adjacent sections (4 Frn thick).
Radioactive ISH was performed as previously described (Bernard et al., 1991; Le Moine et al., 1991) . Probe [O.l ng (m,R, SP, PPA) or 0.2 ng (m,R, m,R)] was deposited on each slide. Sections were hybridized overnight at 40°C, washed, and dried. Ten-micrometer-thick sections were exposed in contact with x-ray film (Kodak X-Omat AR5) for 3 (m,R) or 7 d (m,R or m,R) and then coated with emulsion (Ilford K5) and left in the dark during 2 (m,R) or 6-7 weeks (m,R, m,R). They were revealed, and then either stained with toluidine blue and mounted, or processed for nonradioactive ISH (see below). Sections 3 or 4 pm thick were directly coated with emulsion, exposed for 3 (m,R, SP, PPA) or 8-10 weeks (mzR, m,R, NT), revealed, stained with toluidine blue, and mounted.
The specificity of the ISH reaction for m,R, mZR, and m,R mRNA detection was controlled by addition of m,R, m,R, or m,R unlabeled probe or unrelated unlabeled probe (D, receptor, SRIF, SP) to the hybridization medium containing labeled m,R, m,R, and m,R probe (data not shown). In addition, these probe sequences were shown by Weiner et al. (1990) to recognize specifically the corresponding mRNA in striatal extracts by using Northern blot procedure.
Localization oftwo mRNAs on adjacent sections. Each of two 3-wmthick adjacent sections was hybridized with either a '5S-labeled m,R or m,R probe or a ?S-labeled SP, PPA, or NT probe. Sections of the same neurons were identified on paired sections after toluidine blue staining, and their labeling was compared by using a double-microscopic system coupled to an image analyzer (Histo 200, Biocom, Les Ulis, France).
Simultaneous detection of two mRNAs by combined hvbrldization on the same section.Sections 10 pm thick were hybridized with either an m ,R or an m,R ?S-labeled probe. Following autoradiography, the slides were rinsed in distilled water and then processed for nonradioactive ISH through the emulsion by using a biotinylated PPA (8 @slide) or SRIF (4 r&slide) probe (for further details, see Normand and Bloch, 199 I) . Briefly, sections were hybridized overnight at 40°C and rinsed in saline-sodium citrate. After incubation (I hr) with streptavidin alkaline phosphatase (I: 100; Dakopatts), the signal was revealed with nitroblue tetrazolium-bromochloroindolyl phosphate (GIBCO/Bethesda Research Laboratories). Slides were then rinsed and mounted in Aquamount without counterstaining.
Localization of muscarinic receptor mRNA and choline acetyltrans-,ferase immunoreactivity on adjacent sections. Each of two 4-pm-thick adjacent sections was hybridized with either an m,R, m,R, or m,R 'sSlabeled probe as described above or processed for immunohistochemical detection of choline acetyltransferase (ChAT), a specific marker of cholinergic neurons (Kuhar, 1976) . ChAT was detected using a monoclonal antibody raised against rat ChAT (Boehringer-Mannheim).
Slides were incubated in phosphate-buffered saline (PBS) pH 7.4 with 1% normal aoat serum (NGS) and 0.3% T&on X-100 (TX-100) for 1 hr at 20°C and then wit'h ChkT antibody (1 peg/ml in PBS, pH 7:4, 1% NGS, 0.3% TX-100) for 48 hr at 4°C. Immunoreactivity was revealed with an immunoperoxidase procedure using anti-rat IgG (Dakopatts; 1:200) and rat peroxidase-antiperoxidase (Stemberger-Meyer; 1:200). The slides were then treated with diaminobenzidine (Sigma; 0.05% in Tris buffer sodium, pH 7.6) and the staining intensified with 2% osmium tetroxide. Sections were then dehydrated and mounted. The image analyzer was used to identify neurons that were both immunolabeled and showed ISH signal on adjacent sections. cleus, olfactory tubercle, islands of Calleja, cortex, and septum as described previously (Buckley et al., 1988; Weiner et al., 1990; Vilaro et al., 199 1) . Because of the limited resolution provided by x-ray films, we could not detect the signal for m,R mRNA at this macroscopic level.
Results
The microautoradiographic analysis demonstrated clusters of labeled cells throughout the striatum, the cortex, and the septum with the m,R and the m,R probe. Our counts estimated that 85% of the striatal neurons demonstrated labeling with the m,R probe and 6 1% with the m,R probe. Labeling was present over large-sized (20-30 pm in diameter) (Fig. 1) and medium-sized neurons (10-15 pm in diameter) (Figs. 2, 3) . With the m,R probe, labeling was also noted in cells bordering the lateral ventricle and the choroid plexus cells. The m,R probe provided labeling restricted to the large-sized neurons in the striatum (Fig. 1) .
Identity of the striatal neurons expressing muscarinic receptor genes
In order to establish which muscarinic receptor mRNA was present in chemically identified neuronal populations, we analyzed paired 3-or 4-pm-thick adjacent sections, as well as lopm-thick sections that had been hybridized for the simultaneous detection of two mRNAs. We were thus able to analyze a total of 800 PPA and SP neurons, over 300 SRIF neurons and ChATpositive neurons, and over 40 NT neurons (the latter being very scarce).
As expected, the large-sized neurons were ChAT immunoreactive. Most ofthem contained label for each ofthe muscarinic probes tested: 88% for m,R, 80% for m,R, and 83% for m,R (Fig. 1) .
Comparative analysis of the 3-pm-thick adjacent sections labeled with the SP probe or with the m,R or m,R probes demonstrated that nearly all SP striatal neurons contained m,R and m,R mRNA (m,R, 95%; m,R, 94%) (Figs. 2A,B, 3AJ) . A similar analysis indicated that nearly all (95%) neurons containing PPA mRNA also contained m,R mRNA (Fig. 2C,D) . In contrast, only 39% of PPA neurons contained m,R mRNA (Fig.  3C,D) . The simultaneous detection of PPA mRNA and m,R or m,R mRNA on the same 10 wrn sections confirmed that the m,R signal was present in all PPA neurons, while m,R mRNA was detectable in only a portion of this population (Figs. 2E,  3 .Q. Analysis ofadjacent sections showed that most NT neurons (86%) also showed labeling with the m,R probe (Fig. 2G,H) . In contrast, only 9% of NT cells contained m,R mRNA (Fig. 3G,H) . Double ISH with a biotinylated SRIF probe and a radioactive m,R or m,R probe on same 1 O-pm-thick sections demonstrated that most SRIF neurons (93%) showed labeling with the m,R probe (Fig. 2fl , whereas only 15% were labeled with the m,R probe (Fig. 3F) .
Discussion
The present observations provide evidence that several chemically defined neuronal populations or subpopulations in the striatum contain one or several muscarinic receptor mRNA isotypes (Fig. 4) . This implies that such neurons produce the corresponding receptors and are direct targets for ACh released in the striatum. Our data are thus in agreement with earlier anatomical and electrophysiological investigations (Phelps et al., 1985; Izzo and Bolam, 1988; Kernel et al., 1989; Dawson et al., 1990; Weiner et al., 1990; Gauchy et al., 199 1; Vuillet et al., 1992; Wainer et al., 1984) , including the recent demonstration of immunoreactivity for m,R, m,R, and m,R subtypes in the rat striatum (Levey et al., 1991) . Our results demonstrate, moreover, that the neuronal populations involved in the production of the muscarinic receptors include ACh neurons themselves, where muscarinic receptors may act as autoreceptors. In the other neuronal populations, which may be efferent neurons and interneurons, muscarinic receptors may act as postsynaptic heteroreceptors. Our observations also reveal a heterogeneity of muscarinic receptor gene expression in the striatum and indicate that each neuronal population has its own specific pattern of expression. receptor genes, m,R, m,R, and m,R. They are thus in agreement with pharmacological evidence demonstrating presynaptic inhibition of ACh release by autoreceptors (James and Cubeddu, 1987; Lapchack et al., 1989; Dolezal and Wecker, 1990 ) and with anatomical evidence showing cholinergic terminals in contact with cholinergic cell bodies and dendrites (Phelps et al., 1985) . Also, it has been noted that destruction of cholinergic neurons with the AF64A neurotoxin provokes the loss of presynaptic cholinergic markers, including autoreceptors (Dawson et al., 1990) . Several experiments suggest that the autoreceptors are of the pharmacological M, subtype (Lapchack et al., 1989) that would be encoded by m,R mRNA isotypes (Buckley et al., 1989) ; these data corroborate our observations, and those of Weiner et al. (1990) and Levey et al. (199 1) of m,R mRNA and m,R immunoreactivity in certain large-sized striatal neurons, which are most probably cholinergic. Nevertheless, Weiner et al. (1990) found very little signal for m,R and m,R mRNA in large-sized neurons. However, we saw an intense signal for m,R and m,R mRNA in most cholinergic neurons. Since the probes used were identical in the two studies, the discrepancy may be due to a greater sensitivity provided by our ISH procedure. In any case, we found that reactivity to m,R and m,R probes was always intense and reliable, and together with our appropriate controls for specificity, our data provide strong evidence for the simultaneous expression of three autoreceptor genes in striatal cholinergic neurons. Nevertheless, a certain number of these neurons (12%, 17%, or 20%) did not display, respectively, m,R, m,R, or m,R signal. This may mean that our ISH procedure was not able to detect low mRNA levels in certain neurons. Alternatively, such data may reflect a real absence of muscarinic receptor gene expression in a subpopulation of striatal ACh neurons.
In spite of these reservations, our results clearly indicate that most ACh neurons in the striatum are under the control of ACh via three muscarinic receptors. Each muscarinic receptor isotype has a specific pharmacological profile and has been shown to interact with distinct second messengers. The m,R is preferentially linked to phospholipase C through an unknown G-protein, while m,R and m,R act preferentially on adenylate cyclase through G, protein (Richards, 1991) . While one of these muscat-uric receptors (m,R) is most probably involved in the inhibition of ACh release (Lapchak et al., 1989) , the presence of these three distinct receptor isotypes in the same neurons suggests that they may contribute to other functions related to the activity of the cholinergic neurons, including choline uptake and ACh biosynthesis.
In view of the diversity of neuronal interactions in the striaturn, it is highly probable that its cholinergic neurons are under complex neuronal influences. Indeed, as pointed out earlier, the ACh neurons also express dopamine receptor genes (Le Moine et al., 1990b Moine et al., , 1991 and in particular the D, receptor (D, receptor is found only in a small subpopulation). Recent evidence suggests that the D, and muscarinic receptors could interact in cholinergic neurons to inhibit ACh release by controlling the opening of the same K+ channel (Drukarch et al., 1990) . Thus, cholinergic neurons appear as likely candidates for direct dopamine-ACh interactions in the striatum. In addition, cholinergic neurons also express SP receptors (Elde et al., 1990; Gerfen, 199 1) . In contrast, they have no detectable NT or A, adenosine receptor mRNA (Elde et al., 1990; Schiffmann et al., 1991) . It is probable that further investigations will demonstrate other neurotransmitter receptors in these neurons, especially those for glutamate since glutamate has been shown to stimulate directly ACh release from the striatum through NMDA receptors (Scatton and Lehmann, 1982) .
Medium-sized substance P and enkephalin efferent neurons The striatum contains two main efferent neuronal populations: the striatonigral neurons producing essentially SP, DYN, and GABA, and the striatopallidal neurons producing enkephalins and GABA (Graybiel, 1990) . We have shown here that m,R and m,R are expressed with specific patterns in both SP and enkephalin neurons; the m,R gene appeared expressed in nearly all the efferent neurons. These results thus provide evidence that ACh controls directly the activity ofthe striatal efferent neurons. They confirm and extend previous observations suggesting a direct action of ACh on such neurons. For example, cholinergic terminals contact medium-sized striatonigral neurons (Izzo and Bolam, 1988) and ACh stimulates the release of enkephalins and GABA (Hong et al., 1980; Besson et al., 1987) ; muscarinic agonists inhibit the release of GABA in the striatum (Marchi et al., 1990; Sugita et al., 1991) . In addition, other recent studies have also visualized m,R and m,R mRNA in medium-sized neurons (Weiner et al., 1990 ) and muscarinic binding sites on SP cell bodies (Ariano and Kenny, 1989) . Interestingly, while m,R and m,R mRNAs are expressed in the same efferent neurons, recent immunocytochemical evidence revealed distinct compartmentalization for the corresponding proteins. An m,R immunoreactivity was found in the striatum and in terminals in the substantia nigra, while m,R appeared restricted to the striatum, most probably on cell bodies and dendrites (Levey et al., 199 1) .
Indeed, as shown here, most if not all SP neurons appear under the double control of the m,R and m,R. We and others have recently shown that these neurons also express the D, dopamine receptor gene (Gerfen et al., 1990; Le Moine et al., 1991) indicating that SP neurons are under at least dopaminergic and cholinergic control. ACh is known to exert a direct and indirect inhibitory control on the release of dopamine through muscat-uric receptors (Kernel et al., 1989; Gauchy et al., 199 1) . Direct control may occur through muscarinic receptors located on dopamine terminals (m,R according to Weiner et al., 1990) whereas indirect control may derive from DYN neurons bearing muscarinic receptors (Gauchy et al., 1991) . Since DYN and SP are colocalized in the same neurons (Reiner and Anderson, 1990) our results suggest that the indirect in- (Elde et al., 1990; Le Moine et al., 1990a,b, 199 1; Weiner et al., 1990; Gerfen, 199 1; Schiffmann et al., 199 1) . The presence ofa receptor on a neuron, without a percentage, indicates that over 90% of the neurons in the population contain the receptor mRNA; for receptors under 90%, percentages indicate the proportion of neurons expressing the gene; the absence ofa receptor symbol indicates that the neuronal population does not express the gene. NT receptor is not mentioned since NT receptor gene expression is not detectable in the striatum (Elde et al., 1990) . hibitory control of dopamine release occurs through the m,R and/or the m,R located on the striatonigral neurons. Also, the presence of SP receptors on cholinergic neurons (Gerfen, 199 1) suggests that ACh, as well the SP released from collaterals of striatonigral neurons, may contribute to reciprocal synaptic interactions between the two neuronal populations.
Nearly all striatopallidal enkephalinergic neurons express the m, R gene, but only 39% contain detectable levels of m,R mRNA. While we cannot exclude that the sensitivity of our procedures underestimated the percentage of neurons expressing the m,R gene, the presence of intensely m,R-reactive neurons together with unlabeled ones in the same sections (even after long exposure times) strongly suggests the existence of two subpopulations with respect to m,R gene expression. Weiner et al. (1990) also observed that only 37% of the neurons containing D, receptor mRNA [which we have shown to be enkephalinergic (Le Moine et al., 1990a) ] contained m,R mRNA. If neurons unlabeled with the m,R probe in the present study do express the (Nastuk and Graybiel, 1985; Lowenstein et al., 1990) . Since neurons expressing the m,R gene are evenly distributed in the striatum, it is important to see whether the existence of two enkephalinergic neuronal populations with respect to m,R gene expression could relate to striosome-matrix organization. Mapping of these two cell subpopulations together with striosome-matrix markers may help to answer this question. Since muscarinic binding sites were absent in the globus pallidus (Spencer at al., 1986), one would expect that most muscarinic receptors in enkephalinergic neurons are in cell bodies, dendrites, and collaterals permitting interaction with ACh released in the striatum.
Somatostatin and neurotensin neurons
Since the m,R gene is expressed in most SRIF and NT neurons, as it is in SP and enkephalinergic neurons, the m,R appears to be the main actor in muscarinic control of these neurons. In contrast, m,R may play only a minor role since m,R gene expression was present in only limited subpopulations (15% for SRIF neurons, 9% for NT neurons). That SRIF neurons are under ACh control is supported by ultrastructural studies demonstrating synaptic contacts between cholinergic and NPY neurons (Vuillet et al., 1992) , known to coexpress SRIF (Smith and Parent, 1986) . Also, muscarinic binding sites have been seen over SRIF cell bodies (Ariano and Kenny, 1989) . Vuillet et al. (1992) have recently provided anatomical evidence for reciprocal interactions between ACh and NPY/SRIF interneurons, which may mediate cholinergic effects in the striatum. If so, it remains to be shown that ACh neurons also express the recently cloned NPY receptor (Rimland et al., 199 1) . The evidence for reciprocal interactions between ACh and NT neurons is weaker: muscarinic antagonists decrease NT levels in the striatum (Frey et al., 1988) , but ACh neurons do not express the NT receptor (Elde et al., 1990) .
Conclusion
Our results demonstrate that each identified neuronal population in the striatum is under the direct control of the ACh neurons through the expression of muscarinic receptors, and in particular the m,R. They also show that three major neuronal populations in the striatum, namely, ACh, enkephalins, and SP/ DYN neurons, simultaneously express muscarinic and dopamine receptors (Fig. 4) , thus strongly suggesting that ACh-dopamine interactions may occur at the single-cell level in interneurons and efferent neurons of the striatum. We found that certain of these populations were heterogeneous with respect to the expression of certain muscarinic receptors, especially m,R. Also, since only 85% ofthe medium-sized neurons contain m,R (Weiner et al., 1990) , it is probable that a small proportion of unidentified striatal neurons escape muscarinic control. Nevertheless, it is now clear that nicotinic receptor genes are also expressed in striatal neurons, especially a3 and p, subunits, with a restricted and heterogeneous pattern (Wada et al., 1989) . The experimental strategies we have developed may now prove useful to establish which neuronal populations express these nicotinic receptor gene subtypes. Finally, they may also allow visualization of potential ACh receptor gene expression by glial cells, as has been suggested (Repke and Maderspach, 1982) , in this area of the CNS.
Many investigations have studied the physiological and eventually pathological basis of ACh actions and dysfunctions in the striatum, especially during extrapyramidal movement disorders (Albin et al., 1989) . Indeed, the action of muscarinic antagonists in controlling movement disorders offers strong evidence for the physiological relevance of ACh activities in the striatum. Indeed, cholinergic neurons appear central in striatal circuitry: they are targets for several influences, and in particular corticostriatal (glutamatergic) (Scatton and Lehmann, 1982) and nigrostriatal (dopaminergic) (Dawson et al., 1990; Le Moine et al., 1990b) terminals; they provide inputs to striatal neurons and especially to the GABAergic efferent neurons that are major actors in striatal functions. Surprisingly, although many studies have concentrated on the cellular and molecular mechanisms involved in the control of dopaminoceptive striatal neurons by dopamine, comparatively less attention has been given to action of ACh. It is clear today that dopamine inputs regulate in complex ways the synthesis and release of various neurotransmitters produced by dopaminoceptive efferent neurons, including GABA, SP, and enkephalins (Tang et al., 1983; Young et al., 1986; Normand et al., 1987; Morris et al., 1988; Gerfen et al., 1990, 199 1) . Since most striatal neurons express muscarinic receptor subtypes, and since the heterogeneous distribution of muscarinic receptor mRNAs suggests differential regulation of specific subpopulations, one must expect that ACh also regulates the synthesis and release of several neurotransmitters in the striatum. It is already known that ACh stimulates GABA and enkephalin release (Hong et al., 1980; Besson et al., 1987) . On the basis of our results, experimental conditions interacting with ACh neurotransmission must now help to provide a better understanding of molecular and cellular sites of action of ACh in the striatum.
